Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention

This publication has 29 references indexed in Scilit:

• Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial Infarction
  New England Journal of Medicine, 2001
• Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction
  Journal of the American College of Cardiology, 2000
• Acute Platelet Inhibition With Abciximab Does Not Reduce In-Stent Restenosis (ERASER Study)
  Circulation, 1999
• Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction
  Circulation, 1998
• Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
  The Lancet, 1998
• Myonecrosis After Revascularization Procedures
  Journal of the American College of Cardiology, 1998
• Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization
  New England Journal of Medicine, 1997
• Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study
  The Lancet, 1997
• Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
  New England Journal of Medicine, 1994
• Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.
  Circulation, 1994